Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Oct 20;137(20):2429-2436.
doi: 10.1097/CM9.0000000000003278. Epub 2024 Sep 5.

Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022

Kexin Sun  1 , Bailin Zhang  2 , Shaoyuan Lei  3 , Rongshou Zheng  1 , Xin Liang  4 , Li Li  1 , Xiaolong Feng  5 , Siwei Zhang  1 , Hongmei Zeng  1 , Yifei Yao  1 , Peiqing Ma  5 , Shaoming Wang  1 , Ru Chen  1 , Bingfeng Han  1 , Wenqiang Wei  1 , Jie He  6
Affiliations

Incidence, mortality, and disability-adjusted life years of female breast cancer in China, 2022

Kexin Sun et al. Chin Med J (Engl). .

Abstract

Background: Breast cancer is ranked among the most prevalent malignancies in the Chinese female population. However, comprehensive reports detailing the latest epidemiological data and attributable disease burden have not been extensively documented.

Methods: In 2018, high-quality cancer surveillance data were recorded in 700 population-based cancer registries in China. We extracted data on female breast cancers (International Classification of Diseases, Tenth Revision [ICD-10]: C50) and estimated the incidence and mortality in 2022 according to the baseline data and corresponding trends from 2010 to 2018. Pathological types were classified according to the ICD for Oncology, 3rd Edition codes. Disability-adjusted life years (DALYs) were calculated as the sum of the years of life lost (YLLs) and years lived with disability (YLDs).

Results: In 2022, approximately 357,200 new female breast cancer cases and 75,000 deaths occurred in China, accounting for 15.59% and 7.94% of total new cancer cases and deaths, respectively. The age-standardized incidence rate (ASIR) was 33.04 per 100,000. When analyzed by pathological type, the ASIRs for papillary neoplasms, invasive breast carcinoma, rare and salivary gland-type tumors, and other types were 1.13, 29.79, 0.24, and 1.88 per 100,000, respectively. The age-standardized mortality rate (ASMR) was 6.10 per 100,000. A total of 2,628,000 DALYs were found to be attributable to female breast cancer in China, comprising 2,278,300 YLLs and 349,700 YLDs. The ASIR, ASMR, and age-standardized rate (ASR) for DALYs in urban areas were consistently higher than those in rural areas. We observed a four-fold increase in the ASIR and ASR for DALYs and an eight-fold increase in the ASMR among females over 55 years compared with those aged under 55 years.

Conclusion: These data provide invaluable insights into the latest epidemiology of female breast cancer in China and highlight the urgency for disease prevention and control strategy formulation.

PubMed Disclaimer

Conflict of interest statement

None.

Figures

Figure 1
Figure 1
Estimated incidence, mortality, and DALYs of female breast cancer in China by area and age group, 2022. (A) Incidence cases and rates. (B) Mortality cases and rates. (C) DALYs and DALY rate. DALYs: Disability-adjusted life years.
Figure 2
Figure 2
Morphological distributions of female breast cancer in China by area and age group. (A) Urban and rural areas. (B) Females 0–54 years old and over 55 years old.
See this image and copyright information in PMC

References

    1. Bray F Laversanne M Sung H Ferlay J Siegel RL Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2024;74:229–263. doi: 10.3322/caac.21834. - PubMed
    1. Han B Zheng R Zeng H Wang S Sun K Chen R, et al. Cancer incidence and mortality in China, 2022. J Natl Cancer Center 2024;4:47–53. doi: 10.1016/j.jncc.2024.01.006. - PMC - PubMed
    1. International Agency for Research on Cancer . Cancer Today. Data visualization tools for exploring the global cancer burden in 2022. https://gco.iarc.who.int/today/en. [Last accessed on March 6, 2024].
    1. Sun K Lei L Zheng R Zhang S Zeng H Wang S, et al. Trends in incidence rates, mortality rates, and age-period-cohort effects of female breast cancer–China, 2003-2017. China CDC Wkly 2023;5:340–346. doi: 10.46234/ccdcw2023.065. - PMC - PubMed
    1. International Agency for Research on Cancer . WHO classification of tumors, 5th edition, volume 2: Breast tumors. Lyon: International Agency for Research on Cancer, 2019.